Centessa Pharmaceuticals plc (LON:0ACX)

Centessa Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-223.85	-235.76	-151.09	-216.21	-381.9	-10.66
Depreciation & Amortization	0.32	0.34	0.31	0.13	0.03	-
Other Amortization	0.6	0.6	0.5	-	-	-
Asset Writedown & Restructuring Costs	-	-	-	-	220.45	-
Stock-Based Compensation	33.28	33.55	29.39	24.97	14.85	0.34
Other Operating Activities	34.74	37.05	-20.63	-6.78	16.43	0.24
Change in Accounts Payable	-2.43	-4.59	-2.72	6.35	3.8	-0.05
Change in Other Net Operating Assets	-4.67	26.75	-16.11	-9.01	-9.83	-0.5
Operating Cash Flow	-162.02	-142.06	-160.34	-200.55	-136.16	-10.63
Capital Expenditures	-0.03	-0.03	-0.17	-1.14	-0.19	-
Cash Acquisitions	-	-	-	-	63.44	-
Investment in Securities	-207.85	31.3	-126.84	-	-	-
Other Investing Activities	-	-	-	0.21	-	-
Investing Cash Flow	-207.88	31.27	-127	-0.93	63.26	-
Long-Term Debt Issued	-	109.34	-	-	73.93	1.36
Long-Term Debt Repaid	-	-110.1	-	-	-	-
Net Debt Issued (Repaid)	-0.76	-0.76	-	-	73.93	1.36
Issuance of Common Stock	368.21	370.83	21.12	0.72	344.92	-
Other Financing Activities	-10.1	-5.32	-	-0.26	-0.3	0
Financing Cash Flow	357.35	364.75	21.12	0.46	660.15	1.36
Foreign Exchange Rate Adjustments	-0.51	1.23	0.62	-0.42	1.9	-0.08
Net Cash Flow	-13.06	255.19	-265.61	-201.44	589.15	-9.34
Free Cash Flow	-162.05	-142.09	-160.51	-201.68	-136.34	-10.63
Free Cash Flow Margin	-1080.33%	-	-2342.20%	-	-	-
Free Cash Flow Per Share	-1.32	-1.24	-1.67	-2.16	-1.81	-0.71
Cash Interest Paid	9.24	10.09	9.91	7.28	1.48	-
Cash Income Tax Paid	0.08	0.08	2.94	1.3	-	-
Levered Free Cash Flow	-106.95	-75.19	-96.6	-108.73	-82.08	-
Unlevered Free Cash Flow	-100.43	-68.88	-90.41	-104.18	-80.49	-
Change in Net Working Capital	12.25	-22.32	13.39	-3.29	8.11	-

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.